JP2021169499A5 - - Google Patents

Download PDF

Info

Publication number
JP2021169499A5
JP2021169499A5 JP2021116716A JP2021116716A JP2021169499A5 JP 2021169499 A5 JP2021169499 A5 JP 2021169499A5 JP 2021116716 A JP2021116716 A JP 2021116716A JP 2021116716 A JP2021116716 A JP 2021116716A JP 2021169499 A5 JP2021169499 A5 JP 2021169499A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021116716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021169499A (ja
JP7825343B2 (ja
Filing date
Publication date
Priority claimed from JP2019149385A external-priority patent/JP6915003B2/ja
Application filed filed Critical
Publication of JP2021169499A publication Critical patent/JP2021169499A/ja
Publication of JP2021169499A5 publication Critical patent/JP2021169499A5/ja
Priority to JP2023189564A priority Critical patent/JP2023181543A/ja
Application granted granted Critical
Publication of JP7825343B2 publication Critical patent/JP7825343B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021116716A 2014-03-07 2021-07-14 ヒト血漿カリクレイン阻害剤 Active JP7825343B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023189564A JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461949808P 2014-03-07 2014-03-07
US61/949,808 2014-03-07
US201461981515P 2014-04-18 2014-04-18
US61/981,515 2014-04-18
JP2019149385A JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019149385A Division JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023189564A Division JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Publications (3)

Publication Number Publication Date
JP2021169499A JP2021169499A (ja) 2021-10-28
JP2021169499A5 true JP2021169499A5 (https=) 2021-12-09
JP7825343B2 JP7825343B2 (ja) 2026-03-06

Family

ID=54055948

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016555752A Active JP6574435B2 (ja) 2014-03-07 2015-03-09 ヒト血漿カリクレイン阻害剤
JP2019149385A Active JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤
JP2021116716A Active JP7825343B2 (ja) 2014-03-07 2021-07-14 ヒト血漿カリクレイン阻害剤
JP2023189564A Pending JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016555752A Active JP6574435B2 (ja) 2014-03-07 2015-03-09 ヒト血漿カリクレイン阻害剤
JP2019149385A Active JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023189564A Pending JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Country Status (33)

Country Link
US (14) US10125102B2 (https=)
EP (4) EP3113772B8 (https=)
JP (4) JP6574435B2 (https=)
KR (2) KR102736869B1 (https=)
CN (2) CN106257976B (https=)
AU (3) AU2015226855C1 (https=)
BR (1) BR112016020199A8 (https=)
CA (2) CA2941380C (https=)
CY (2) CY1123810T1 (https=)
DK (2) DK3113772T3 (https=)
EA (1) EA036251B1 (https=)
ES (3) ES2932406T3 (https=)
FR (1) FR21C1048I2 (https=)
HR (2) HRP20221373T1 (https=)
HU (3) HUE060660T2 (https=)
IL (2) IL280785B2 (https=)
LT (3) LT3828173T (https=)
LU (1) LUC00233I2 (https=)
MA (1) MA53399B1 (https=)
MX (2) MX377845B (https=)
MY (1) MY199131A (https=)
NL (1) NL301142I2 (https=)
NO (1) NO2022046I1 (https=)
NZ (2) NZ762034A (https=)
PH (1) PH12016501750B1 (https=)
PL (2) PL3113772T3 (https=)
PT (2) PT3828173T (https=)
RS (2) RS63763B1 (https=)
SG (2) SG11201607267SA (https=)
SI (1) SI3113772T1 (https=)
SM (2) SMT202300002T1 (https=)
WO (1) WO2015134998A1 (https=)
ZA (1) ZA201606320B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
NO2760821T3 (https=) 2014-01-31 2018-03-10
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
DK4019022T3 (en) 2015-10-01 2024-02-19 Biocryst Pharm Inc Human plasma kallikrein inhibitors
DK3464271T3 (da) 2016-05-31 2020-06-15 Kalvista Pharmaceuticals Ltd Pyrazolderivater som plasma-kallikreininhibitorer
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
PT3716952T (pt) 2017-11-29 2022-04-14 Kalvista Pharmaceuticals Ltd Formas de administração que incluem um inibidor de calicreína plasmática
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3953395B1 (en) * 2019-04-08 2026-05-06 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
WO2021025969A1 (en) 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN114206839B (zh) * 2019-08-06 2025-03-07 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
CN115210230A (zh) * 2020-03-04 2022-10-18 南京明德新药研发有限公司 杂环类化合物
CN115989224B (zh) * 2020-06-16 2025-02-25 默沙东有限责任公司 血浆激肽释放酶抑制剂
KR20230038526A (ko) 2020-07-10 2023-03-20 머크 샤프 앤드 돔 엘엘씨 혈장 칼리크레인 억제제
WO2022060842A1 (en) * 2020-09-15 2022-03-24 The Trustees Of Columbia University In The City Of New York Systems and methods for predicting graft dysfunction with exosome proteins
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法
WO2025122555A1 (en) * 2023-12-05 2025-06-12 Valo Health, Inc. S1p 1 receptor agonists and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
DE3633840A1 (de) 1986-10-04 1988-04-14 Hoechst Ag Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic, Inc., Minneapolis, Minn. Intraluminale prothese mit wirkstoffeluierung.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
AU730224B2 (en) * 1996-12-23 2001-03-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
SK174699A3 (en) * 1997-06-19 2000-08-14 Du Pont Pharm Co Inhibitors of factor xa with a neutral p1 specificity group
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
EP1042299A1 (en) * 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
MXPA01008142A (es) * 1999-02-10 2003-07-21 Welfide Corp Compuestos de amida, y uso medicinal de los mismos.
EP1175419B1 (en) * 1999-04-02 2003-05-28 Bristol-Myers Squibb Pharma Company Aryl sulfonyls as factor xa inhibitors
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
KR100751981B1 (ko) 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
KR20040043089A (ko) 2000-09-22 2004-05-22 브리스톨-마이어스 스퀴브 파마 컴파니 인자 Ｘａ 억제제의 효과적인 제조 방법
CA2442557C (en) 2001-04-12 2008-12-23 F. Hoffmann-La Roche Ag Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii
US7038057B2 (en) * 2001-08-13 2006-05-02 E.I. Du Pont De Nemours And Company Substituted 1H-dihydropyrazoles, their preparation and use
TWI312274B (en) * 2001-08-13 2009-07-21 Du Pont Method for controlling particular insect pests by applying anthranilamide compounds
TWI283164B (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
CN1298706C (zh) * 2001-09-21 2007-02-07 杜邦公司 杀虫二酰胺类
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
US20060148858A1 (en) 2002-05-24 2006-07-06 Tsuyoshi Maekawa 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
BR0311707A (pt) * 2002-06-13 2005-03-15 Du Pont Composto, composição e método de controle de pelo menos uma praga invertebrada
DE10229070A1 (de) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
BRPI0407088A (pt) 2003-01-28 2006-01-24 Aventis Pharma Sa Produtos n-aril-heteroaromáticos, composições contendo os mesmos e seu uso
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
KR20060135881A (ko) 2004-04-13 2006-12-29 이 아이 듀폰 디 네모아 앤드 캄파니 안트라닐아미드 살충제
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
US20060069270A1 (en) 2004-09-27 2006-03-30 Rafael Shapiro Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
AU2005306363B2 (en) 2004-11-18 2012-08-09 E. I. Du Pont De Nemours And Company Anthranilamide insecticides
MX2007006790A (es) * 2004-12-07 2007-08-15 Toyama Chemical Co Ltd Novedosos derivado de acido antranilico o sal del mismo.
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
JP5186751B2 (ja) * 2005-10-14 2013-04-24 住友化学株式会社 ヒドラジド化合物およびその有害生物防除用途
PL1937664T3 (pl) 2005-10-14 2011-11-30 Sumitomo Chemical Co Związki hydrazydowe i ich zastosowanie jako pestycydy
PE20070795A1 (es) 2005-10-28 2007-08-24 Lilly Co Eli Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
ATE525072T1 (de) 2006-02-09 2011-10-15 Athersys Inc Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen
EP2051975B1 (de) * 2006-05-16 2012-09-12 Boehringer Ingelheim International GmbH Substituierte prolinamide, deren herstellung und deren verwendung als arzneimittel
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
BRPI0718677A2 (pt) 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
KR20090094125A (ko) * 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
CN101298451B (zh) 2007-04-30 2013-01-30 中国中化股份有限公司 苯甲酰胺类化合物及其应用
WO2008134969A1 (fr) 2007-04-30 2008-11-13 Sinochem Corporation Composés benzamides et leurs applications
MX2011006319A (es) 2008-12-18 2011-06-24 Bayer Cropscience Ag Amidas del acido antranilico sustituidas con tetrazol como plaguicidas.
CN102365278B (zh) 2009-03-26 2015-05-06 先正达参股股份有限公司 杀虫化合物
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
AU2010330743A1 (en) 2009-12-18 2012-07-05 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
JPWO2011118818A1 (ja) 2010-03-26 2013-07-04 味の素株式会社 アミジノアニリン誘導体
CN102285963B (zh) 2010-06-21 2014-04-09 中国中化股份有限公司 3-甲氧基吡唑酰胺类化合物及其应用
AU2011291034A1 (en) 2010-08-20 2013-03-14 Grünenthal GmbH Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
JP2013545740A (ja) 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
EP2702055A1 (en) 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
WO2012142308A1 (en) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2013036232A2 (en) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
CN104066720A (zh) 2011-11-09 2014-09-24 格吕伦塔尔有限公司 作为类香草素受体配体的具有被含so2-基团取代的苯基基团的被取代的基于吡唑基的羧酰胺和脲衍生物
CN103467380B (zh) 2013-09-29 2015-06-24 南开大学 一类取代苯基吡唑酰胺衍生物及其制备方法和应用
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
CN114206839B (zh) 2019-08-06 2025-03-07 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成

Similar Documents

Publication Publication Date Title
JP2021169499A5 (https=)
JP2017507160A5 (https=)
JP2021523221A5 (https=)
JP2024050527A5 (https=)
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
JP2022552156A5 (https=)
JP2016504387A5 (https=)
JP2016517417A5 (https=)
JP2024528036A5 (https=)
RU2006112428A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JPS6216480A (ja) 複素環式置換フエノキシアルキル−イソオキサゾ−ルおよび−フラン、それらの製法および抗ウイルス剤としての用法
JP2007502295A5 (https=)
JP2024516033A5 (https=)
JP2006507355A5 (https=)
JP2020532545A5 (https=)
JP2022137237A5 (https=)
JP2023535815A5 (https=)
JP2019528279A5 (https=)
JP2018529721A5 (https=)
KR101208748B1 (ko) 2-치환-5-옥소-3-피라졸리딘카르복실레이트의 제조 및 용도
CN114026087A (zh) 三并环类化合物及其制备方法和用途
JP2022533939A5 (https=)
JP2022119852A5 (https=)
JP2024523488A5 (https=)
JP2013508385A (ja) 治療上有用な、受容体修飾薬としてのクマリン化合物